Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

Insilico Medicine develops highly selective FGFR2/3 dual inhibitor for cancer treatment

Fibroblast growth factor receptors (FGFRs) are critical drivers of oncogenesis in various solid tumors, including urothelial carcinoma, hepatocellular carcinoma, ovarian cancer and lung adenocarcinoma.

7 Feb 2025

Insilico Medicine doses first patient in Phase I Trial of ISM6331 for mesothelioma

Insilico Medcine( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced the first patient has been dosed in the global multicenter Phase I Trial of ISM6331, a novel pan-TEAD inhibitor developed from Insilico's generative chemistry engine Chemistry42, for the treatment of mesothelioma and other solid tumors.

22 Jan 2025

Groundbreaking trial finds levofloxacin effective against multidrug-resistant TB

A clinical trial published in the New England Journal of Medicine showed that the oral antibiotic levofloxacin taken once-daily for six months substantially reduced the risk of developing drug-resistant tuberculosis (TB), and almost halved adults' and children's risk of developing multidrug-resistant TB.

15 Jan 2025

Pharmacokinetics of berberine and astragaloside IV in normal and diabetic rats

Announcing a new publication for Acta Materia Medica journal. The UPLC-QqQ-MS/MS method was established, validated, and used for the simultaneous detection of berberine (BBR), astragaloside IV (AST), and the main metabolites to demonstrate the comparative pharmacokinetics of BBR and AST in normal and T2DM rats.

15 Jan 2025

AI-designed drug shows promise for inflammatory bowel disease

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announces positive results from two Phase I studies in Australia and China of ISM5411, a novel gut-restricted and PHD specific Inhibitor designed and optimized with the support of Insilico's Chemistry42 commercially-available generative reinforcement learning platform, for Inflammatory Bowel Disease (IBD).

8 Jan 2025

Insilico Medicine nominates ISM1745 as preclinical candidate for MTAP-deleted cancers

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced the nomination of ISM1745, a potentially best-in-class MTA cooperative PRMT5 inhibitor with AI-powered novel scaffold, as preclinical candidate (PCC) for the treatment of MTAP-deleted cancers.

2 Jan 2025

Pharmacokinetics and chemical composition of Shenqi Fuzheng

Shenqi Fuzheng (SQ) is a widely used Chinese medicine formula known for its immune-enhancing and Qi-supplementing properties.

23 Dec 2024

Quabodepistat combo shows promise for safer, faster tuberculosis treatment

Study highlights the safety and early bactericidal activity of quabodepistat when combined with delamanid, bedaquiline, or both, offering potential for shorter and more tolerable tuberculosis treatment regimens.

1 Dec 2024

How breast cancer patients respond to tamoxifen may be linked to the gut microbiome

A new study has shown that variation in the microbiota of the human gut impacts the pharmacokinetics of tamoxifen and thus the effectiveness of the drug.

25 Nov 2024

Small brain-penetrating molecule offers hope for treating aggressive brain tumors

Gliocidin selectively kills glioblastoma cells by inhibiting nucleotide synthesis, showing potential as a therapeutic option in combination with temozolomide.

21 Nov 2024

Lupus Research Alliance announces 33 studies to be presented at ACR Convergence 2024

The Lupus Research Alliance (LRA), the largest private funder of lupus research worldwide, today announced that a total of 33 studies, funded by the organization or supported by its clinical research affiliate Lupus Therapeutics, will be presented at ACR Convergence 2024.

5 Nov 2024

Researchers develop the first polymer-based therapeutic for Huntington’s disease

Breakthrough polymer-based therapy shows promise in reversing Huntington's disease symptoms by preventing toxic protein clumps and enhancing neuronal survival.

4 Nov 2024

Rice University leads development of innovative bioelectronic implant for obesity and diabetes

Rice University is part of a multiuniversity research team that has secured an award of up to $34.9 million from the Advanced Research Projects Agency for Health (ARPA-H) to accelerate the development of a bioelectronic implant designed to improve adherence for obesity and type 2 diabetes (T2D) treatment while reducing development and manufacturing costs.

3 Oct 2024

Researchers develop four new regimens to treat people with multidrug-resistant TB meningitis

In a preliminary study with a small number of humans, rabbits and mice, researchers at Johns Hopkins Children's Center say they have developed four new regimens that have the potential to treat and save the lives of people with multidrug-resistant (MDR) tuberculous (TB) meningitis.

16 Aug 2024

New insights into the pharmacokinetics of remdesivir in treating SARS-CoV-2 in pregnant women

A new study provides important insights into the pharmacokinetics and safety of intravenous remdesivir in treating the SARS-CoV-2 coronavirus in pregnant women.

13 Aug 2024

New review highlights advances in diabetes research and treatment

A new paper surveying advances in diabetes pathogenesis and treatment explores the complex factors contributing to the onset and progression of the disease, suggesting that an understanding of these dynamics is key to developing targeted interventions to reduce the risk of developing diabetes and managing its complications.

25 Jul 2024

Pharmacokinetics News and Research

Further Reading

Insilico Medicine develops highly selective FGFR2/3 dual inhibitor for cancer treatment

Insilico Medicine doses first patient in Phase I Trial of ISM6331 for mesothelioma

Groundbreaking trial finds levofloxacin effective against multidrug-resistant TB

Pharmacokinetics of berberine and astragaloside IV in normal and diabetic rats

AI-designed drug shows promise for inflammatory bowel disease

Insilico Medicine nominates ISM1745 as preclinical candidate for MTAP-deleted cancers

Pharmacokinetics and chemical composition of Shenqi Fuzheng

Quabodepistat combo shows promise for safer, faster tuberculosis treatment

How breast cancer patients respond to tamoxifen may be linked to the gut microbiome

Small brain-penetrating molecule offers hope for treating aggressive brain tumors

Lupus Research Alliance announces 33 studies to be presented at ACR Convergence 2024

Researchers develop the first polymer-based therapeutic for Huntington’s disease

Rice University leads development of innovative bioelectronic implant for obesity and diabetes

Researchers develop four new regimens to treat people with multidrug-resistant TB meningitis

New insights into the pharmacokinetics of remdesivir in treating SARS-CoV-2 in pregnant women

New review highlights advances in diabetes research and treatment

Safety-focused summary of GLP-1 receptor agonists in diabetes, obesity, and beyond

Tailoring polymeric micelles for improved olaparib solubility and drug release

New drug-like molecules show promise in preventing influenza by blocking virus entry

New PET imaging agent shows promise in visualizing lesions in clear cell renal cell cancer patients

Industry Focus - Biopharma eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News